Hepion Pharmaceuticals, Inc.

( )
HEPA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc 2.57%58.766.5%$173.62m
CTLTCatalent, Inc. 3.40%76.242.1%$127.11m
VRXValeant Pharmaceuticals International, Inc. -4.83%17.5414.1%$103.21m
JAZZJazz Pharmaceuticals Plc -1.14%107.542.4%$96.91m
BHCBausch Health Cos., Inc. -4.83%17.540.0%$73.39m
UTHRUnited Therapeutics Corp. -0.69%117.7814.3%$69.53m
ICPTIntercept Pharmaceuticals, Inc. -2.91%44.0516.8%$60.95m
AXSMAxsome Therapeutics, Inc. 2.34%85.841.9%$53.99m
PCRXPacira Biosciences, Inc. 4.38%56.5410.3%$51.91m
ZGNXZogenix, Inc. 2.54%28.287.5%$49.40m
PRGOPerrigo Co. Plc -0.54%54.906.8%$48.11m
MYOKMyoKardia, Inc. 1.33%95.291.8%$46.96m
ARGXargenx SE 2.44%251.380.0%$42.46m
GWPHGW Pharmaceuticals Plc -0.48%129.006.2%$39.30m
AMRNAmarin Corp. Plc 0.45%6.771.6%$37.59m

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.